Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis

ClinicalTrials.gov ID: NCT02762500

Public ClinicalTrials.gov record NCT02762500. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Assess the Efficacy and Safety of Induction Therapy With LYC-30937-EC in Subjects With Active Ulcerative Colitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to evaluate the efficacy and safety of LYC-30937-EC given orally once daily in subjects with active ulcerative colitis (UC) defined as a total Mayo score (TMS) of 4-11 inclusive, with an endoscopic score of ≥ 2 and a rectal bleeding score of ≥ 1 at screening.

Study identification

NCT ID
NCT02762500
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Lycera Corp.
Industry
Enrollment
124 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2016
Primary completion
Apr 30, 2018
Completion
Apr 30, 2018
Last update posted
Apr 1, 2019

2016 – 2018

United States locations

U.S. sites
26
U.S. states
13
U.S. cities
23
Facility City State ZIP Site status
Lycera Investigational Site Little Rock Arkansas 72212 —
Lycera Investigational Site Long Beach California 90822 —
Lycera Investigational Site Mission Hills California 91345 —
Lycera Investigational Site Rialto California 92377 —
Lycera Investigational Site Hollywood Florida 33021 —
Lycera Investigational Site Miami Florida 33176 —
Lycera Investigational Site Decatur Georgia 30033 —
Lycera Investigational Site Marietta Georgia 30060 —
Lycera Investigational Site Chicago Illinois 60637 —
Lycera Investigational Site Louisville Kentucky 40202 —
Lycera Investigational Site Baton Rouge Louisiana 70809 —
Lycera Investigational Site Ann Arbor Michigan 48109 —
Lycera Investigational Site Brooklyn New York 11230 —
Lycera Investigational Site New York New York 10024 —
Lycera Investigational Site The Bronx New York 10461 —
Lycera Investigational Site Greenville North Carolina 27834 —
Lycera Investigational Site Flourtown Pennsylvania 19031 —
Lycera Investigational Site Philadelphia Pennsylvania 19104 —
Lycera Investigational Site Sayre Pennsylvania 18840 —
Lycera Investigational Site Nashville Tennessee 37212 —
Lycera Investigational Site Union City Tennessee 38261 —
Lycera Investigational Site. Houston Texas 76092 —
Lycera Investigational Sites Houston Texas 77004 —
Lycera Investigational Site Houston Texas 77004 —
Lycera Investigational Site Houston Texas 77030 —
Lycera Investigational Site San Antonio Texas 78229 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02762500, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 1, 2019 · Synced Sep 28, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02762500 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →